BIO-LIBRA Study Reveals Gender Disparities in Cardiac Device Outcomes for Non-Ischemic Cardiomyopathy
Key Insights
The BIO-LIBRA study achieved unprecedented female representation at 48% in cardiac device trials, revealing that males with non-ischemic cardiomyopathy (search) face twice the risk of death or life-threatening arrhythmias compared to females.
One-year results showed 13% of males experienced adverse outcomes versus 6% of females, representing a 52% lower risk for female patients with implantable cardiac defibrillators.
Researchers overcame traditional enrollment barriers by scheduling visits with routine care, using remote monitoring, and removing age or comorbidity exclusions that disproportionately affected female participation.
The BIO-LIBRA study has revealed significant gender differences in cardiac device outcomes for patients with non-ischemic cardiomyopathy (search), with males facing twice the risk of death or life-threatening heart rhythm abnormalities compared to females. Published in eClinicalMedicine, this landmark trial achieved nearly 48% female enrollment—an unprecedented level in cardiac device research that enabled researchers to identify critical gender-based differences in treatment outcomes.
Breakthrough Gender Representation Reveals Clinical Insights
The study enrolled 1,000 patients with non-ischemic cardiomyopathy (search), a condition involving weakening of heart muscle that is more common in females. Participants received either an implantable cardioverter defibrillator (search) (ICD) or a cardiac resynchronization therapy defibrillator (search) (CRT-D) to monitor heart rhythm and deliver impulses to correct irregular beats and coordinate heart contraction.
"This is the first study that had a large enough number of females enrolled to show this difference," said Valentina Kutyifa, MD, PhD, professor of Medicine, Cardiology Heart Research at the University of Rochester Medical Center and co-lead of BIO-LIBRA. "We learned that patients with non-ischemic cardiomyopathy (search) do well with these devices, but they still have a residual risk of developing life-threatening ventricular arrhythmias (search) or dying, and this risk is lower in females."
Significant Gender Disparities in One-Year Outcomes
One year after device implantation, the results revealed striking differences between male and female patients. Thirteen percent of males in the study had experienced a life-threatening heart rhythm abnormality or died, compared to just six percent of females. While the rate of arrhythmias or death among female participants remains clinically meaningful, it represents a 52% lower risk compared to their male counterparts.
The trial will continue monitoring patients to evaluate differences in arrhythmia and death rates between male and female patients at three years after device implantation, providing longer-term data on gender-specific outcomes.
Addressing Historical Underrepresentation
Despite comprising roughly half of the global population, females have been historically underrepresented in medical research, particularly in device trials. Original trials testing ICDs and CRT-Ds focused on ischemic cardiomyopathy (search), which is more common in males, and enrolled only 15-29% female participants. This data gap may have contributed to females being less likely to receive treatment with ICDs or CRT-Ds.
When Kutyifa and co-lead Jeanne Poole, MD, professor of Medicine at UW Medicine (search), designed the BIO-LIBRA study, they specifically aimed to address this representation gap and better reflect the demographics of patients with non-ischemic cardiomyopathy (search).
Innovative Enrollment Strategies
To overcome traditional barriers preventing female enrollment, the researchers implemented several strategic modifications. "Clinical trials might be too much of a time demand, too much to juggle with family, because females are still more likely to be caregivers," Kutyifa explained. "Females may not know about studies, and doctors and study staff may assume females are at low risk or ineligible for a study."
The research team designed study visits to coincide with regular care appointments and utilized remote monitoring to reduce time demands on participants. Unlike previous studies, they eliminated exclusions based on age or comorbidities that could inadvertently and disproportionately exclude females. Additionally, they educated study teams about the importance of increasing female participation and provided practical guidance for enrolling more diverse participants.
Clinical Implications and Future Impact
The study's success in achieving representative enrollment extended beyond gender, with researchers enrolling greater proportions of several typically underrepresented groups. "Our data will help clinicians identify patients at higher risk and potentially intensify their treatment," Kutyifa noted.
The BIOTRONIK-funded study demonstrates that improving demographic representation in clinical trials provides more accurate risk stratification and treatment guidance for all patients. "As we've shown in this study, enrolling participants that better reflect the actual patient population benefits everyone, not just those who have been left out in the past," Kutyifa concluded.